By Zachary Zagger ( March 11, 2015, 4:20 PM EDT) -- Kythera Biopharmaceuticals Inc. said Tuesday it will raise just over $125 million in a public share offering, just days after its lead drug candidate to treat double chins received unanimous approval from a U.S. Food and Drug Administration advisory committee....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.